Prosecution Insights
Last updated: September 17, 2026
Application No. 18/153,780

NANOTEXTURED SILICON BIOSENSORS

Final Rejection §112
Filed
Jan 12, 2023
Priority
Feb 20, 2019 — provisional 62/808,259 +1 more
Examiner
GIERE, REBECCA M
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Advanced Silicon Group Inc.
OA Round
4 (Final)
74%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
380 granted / 515 resolved
+13.8% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
31 currently pending
Career history
544
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
24.0%
-16.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 515 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1, 14 and 15 have been amended. Claims 16-23 have been added. Claims 2, 5-6 and 11 have been cancelled. Claims 1, 3-4, 7-10 and 12-23 are pending. Response to Arguments Applicant’s arguments and amendments filed 06/29/2026 have been considered and are found to be persuasive as amendments have incorporated allowable subject matter of previously indicated claims 11 and 15. However, the claims remain unpatentable based on the indefinite rejections described below because the allowable subject matter added to the claims needs to be more clearly integrated into the entirety of the claim. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3-4, 7-10 and 12-23 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is unclear because the claim states exposing the subsensors to a solution of interest…to deduce a concentration of a particular material. However, the claim then goes on to state measurement signals from multiple proteins and it is unclear where the multiple proteins (first and second proteins) have originated. Additionally, the last paragraph also states determining a concentration of a first protein and it is unclear if this first protein is an additional concentration than the previously recited particular material. Claim 16 is unclear because it states a second protein but it is unclear where the second protein has originated since it hasn’t been limited to coming from the solution of interest or having relation to the particular material. Additionally, it is unclear if the first or second protein are intended to be the particular material or if these are three different concentrations being deduced. Claim 23 is unclear because the claim states exposing the subsensors to a solution of interest…to deduce a concentration of a particular material. However, the claim then goes on to state measurement signals from multiple proteins and it is unclear where the multiple proteins (first and second proteins) have originated. Additionally, the last paragraph also states determining a concentration of a first protein and it is unclear if this first protein is an additional concentration than the previously recited particular material. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 10 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 10 states that different subsensors are used in combination to separate out signals from multiple proteins, however claim 1 has been amended to include separating measurement signals using the multiple subsensors. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA M GIERE whose telephone number is (571)272-5084. The examiner can normally be reached M-F 8:30-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy L Nguyen can be reached at 571-272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA M GIERE/Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Show 2 earlier events
Nov 17, 2025
Response Filed
Mar 09, 2026
Final Rejection mailed — §112
Apr 16, 2026
Response after Non-Final Action
Apr 28, 2026
Request for Continued Examination
Apr 29, 2026
Response after Non-Final Action
Jun 17, 2026
Non-Final Rejection mailed — §112
Jun 29, 2026
Response Filed
Sep 10, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12730105
METHOD FOR DROPLET LOADING INTO NANOWELLS
4y 0m to grant Granted Sep 08, 2026
Patent 12710418
Resonant nanophotonic biosensors
3y 4m to grant Granted Aug 18, 2026
Patent 12704510
SIGNAL AMPLIFICATION IN PLASMONIC SPECIFIC-BINDING PARTNER ASSAYS
4y 8m to grant Granted Aug 11, 2026
Patent 12687553
METHOD FOR CAPTURING AND IDENTIFYING CELLULAR AGGLUTINATES FOR DETECTING MULTIPLEX ANTI-ERYTHROCYTE ANTIBODIES
3y 11m to grant Granted Jul 21, 2026
Patent 12643103
SYSTEMS, DEVICES AND METHODS FOR MULTIPLEXED ANALYSIS
3y 9m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+32.2%)
3y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 515 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month